[1] Fahad Ullah M. Breast cancer: current perspectives on the disease status[J]. Adv Exp Med Biol, 2019, 1152:51-64. DOI: 10.1007/978-3-030-20301-6_4.
[2] Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 65:18-31. DOI: 10.1016/j.bpobgyn. 2019.11.006.
[3] Kolak A, Kamińska M, Sygit K, et al. Primary and secondary prevention of breast cancer[J]. Ann Agric Environ Med, 2017, 24(4):549-553. DOI: 10.26444/aaem/75943.
[4] Woolston C. Breast cancer[J]. Nature, 2015, 527(7578):S101. DOI: 10.1038/527S101a.
[5] Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer[J]. Cancer Treat Rev, 2019, 79:101888. DOI: 10.1016/j.ctrv.2019.08.004.
[6] Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer[J]. Chin Clin Oncol, 2020, 9(3):32. DOI: 10.21037/cco-20-123.
[7] Xiaokaiti Y, Li X. Natural product regulates autophagy in cancer[J]. Adv Exp Med Biol, 2020, 1207:709-724. DOI: 10.1007/978-981-15-4272-5_53.
[8] Jayasekera J, Mandelblatt JS. Systematic review of the cost effectiveness of breast cancer prevention, screening, and treatment interventions[J]. J Clin Oncol, 2020, 38(4):332-350. DOI: 10.1200/JCO.19.01525.
[9] Lestari ML, Indrayanto G. Curcumin[J]. Profiles Drug Subst Excip Relat Methodol, 2014, 39:113-204. DOI: 10.1016/B978-0-12-800173-8.00003-9.
[10] Ramezani M, Hatamipour M, Sahebkar A. Promising anti-tumor properties of bisdemethoxycurcumin: a naturally occurring curcumin analogue[J]. J Cell Physiol, 2018, 233(2):880-887. DOI: 10.1002/jcp.25795.
[11] Atanasov AG, Zotchev SB, Dirsch VM, et al. Natural products in drug discovery: advances and opportunities[J]. Nat Rev Drug Discov, 2021, 20(3):200-216. DOI: 10.1038/s41573-020-00114-z.
[12] Hermawan A, Putri H. Current report of natural product development against breast cancer stem cells[J]. Int J Biochem Cell Biol, 2018, 104:114-132. DOI: 10.1016/j.biocel.2018.09.012.
[13] Liao CL, Chu YL, Lin HY, et al. Bisdemethoxycurcumin suppresses migration and invasion of human cervical cancer HeLa cells via inhibition of NF-ĸB, MMP-2 and -9 pathways[J]. Anticancer Res, 2018, 38(7):3989-3997. DOI: 10.21873/anticanres.12686.
[14] Qiu C, Liu K, Zhang S, et al. Bisdemethoxycurcumin inhibits hepatocellular carcinoma proliferation through Akt inactivation via CYLD-mediated deubiquitination[J]. Drug Des Devel Ther, 2020, 14:993-1001. DOI: 10.2147/DDDT.S231814.
[15] Xu J, Yang H, Zhou X, et al. Bisdemethoxycurcumin suppresses migration and invasion of highly metastatic 95D lung cancer cells by regulating E-cadherin and vimentin expression, and inducing autophagy[J]. Mol Med Rep, 2015, 12(5):7603-7608. DOI: 10.3892/mmr.2015. 4356.
[16] 苗久旺,荆雪宁,高荧,等.自噬对双去甲氧基姜黄素诱导肝癌HepG2细胞凋亡作用的影响[J].中国实验方剂学杂志,2018,24(17):167-171. DOI:10.13422/j.cnki.syfjx. 20181525.
[17] Lee PJ, Woo SJ, Jee JG, et al. Bisdemethoxycurcumin Induces apoptosis in activated hepatic stellate cells via cannabinoid receptor 2[J]. Molecules, 2015, 20(1):1277-1292. DOI: 10.3390/molecules20011277.
[18] 刘学键,刘永,杨清华,等.脑胶质瘤CD47表达水平及对细胞增殖和迁移影响[J].中华肿瘤防治杂志,2020,27(15):1195-1202. DOI:10.16073/j.cnki.cjcpt.2020.15.03.
[19] Ma ZJ, Lu L, Yang JJ, et al. Lariciresinol induces apoptosis in HepG2 cells via mitochondrial-mediated apoptosis pathway[J]. Eur J Pharmacol, 2018, 821:1-10. DOI: 10.1016/j.ejphar.2017.12.027.
[20] Fasoulakis Z, Koutras A, Syllaios A, et al. Breast cancer apoptosis and the therapeutic role of luteolin[J]. Chirurgia (Bucur), 2021, 116(2):170-177. DOI: 10.21614/chirurgia.116.2.170.
[21] Cao X, Fu M, Bi R, et al. Cadmium induced BEAS-2B cells apoptosis and mitochondria damage via MAPK signaling pathway[J]. Chemosphere, 2021, 263:128346. DOI: 10.1016/j.chemosphere.2020.128346.
|